Loading clinical trials...
Loading clinical trials...
Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression
Conditions
Interventions
Thymoglobulin
Belatacept
+4 more
Locations
20
United States
California Institute Of Renal Research
San Diego, California, United States
California Pacific Medical Center
San Francisco, California, United States
University Of Colorado
Aurora, Colorado, United States
Yale University
New Haven, Connecticut, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Emory Univeristy
Atlanta, Georgia, United States
Start Date
December 31, 2015
Primary Completion Date
May 2, 2019
Completion Date
May 2, 2019
Last Updated
June 22, 2021
NCT05753930
NCT04128189
NCT06568549
NCT04870437
NCT07415421
NCT06958796
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions